Welcome to our dedicated page for TriSalus Life Sciences SEC filings (Ticker: TLSI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
TriSalus Life Sciences, Inc. filings document operating results, governance actions and capital-structure matters for an oncology-focused medical technology company. Form 8-K reports cover financial results, business updates, guidance, material events, leadership changes, board composition and Regulation FD disclosures tied to TriNav, PEDD and related oncology development activity.
Proxy materials describe shareholder voting matters, director elections, board committees, executive compensation and equity awards. The filing record also includes capital-structure disclosures for common stock and warrants, material-agreement categories, clinical or regulatory disclosure topics and risk-related information associated with commercializing PEDD infusion systems and developing investigational therapies for solid tumors.
TriSalus Life Sciences director William Valle reported an open-market purchase of company stock. On this Form 4, he bought 30,487 shares of TriSalus Life Sciences, Inc. common stock at a price of $4.10 per share. Following this transaction, he directly owns 30,487 common shares.
TriSalus Life Sciences CEO Mary T. Szela reported an open-market purchase of 30,487 shares of common stock at $4.10 per share. After this buy, she directly owns 773,289 shares, increasing her personal stake in the company.
TriSalus Life Sciences director Michael P. Stansky reported significant open-market purchases of the company’s common stock. He bought 243,900 shares directly at $4.10 per share and 117,198 shares at $4.10 per share through Skyview Investments LLC.
After these transactions, his direct holdings total 787,132 common shares, and his indirect holdings through Skyview Investments LLC total 199,698 common shares, reflecting continued equity ownership aligned with the company’s shareholders.
TriSalus Life Sciences filed a prospectus supplement to offer 9,756,100 shares of Common Stock at a public offering price of $4.10 per share, with a 30-day underwriter option for 1,463,415 additional shares. Net proceeds are estimated at approximately $37.0M (or $42.64M if the option is fully exercised) to be used for general corporate purposes.
The prospectus states pro forma shares outstanding of 59,811,590 after the offering (or 61,275,005 if the over-allotment is exercised). Preliminary unaudited results disclose $13.2M in fourth-quarter 2025 revenue, full-year 2025 revenue of $45.2M, and cash and cash equivalents of approximately $20.4M as of December 31, 2025.
TriSalus Life Sciences, Inc. has entered into an underwriting agreement for a public offering of 9,756,100 shares of its common stock at $4.10 per share. The company also granted underwriters a 30-day option to buy up to 1,463,415 additional shares to cover over-allotments.
Gross proceeds are expected to be about $40.0 million, with estimated net proceeds of approximately $37.0 million without exercising the option, or about $42.64 million if the option is fully exercised. TriSalus plans to use the cash for general corporate purposes, including capital spending, working capital, and administrative costs.
The deal is being made under an effective Form S-3 shelf registration, with Lake Street Capital Markets acting as sole book-runner. The offering is expected to close around February 23, 2026, and the company, its officers, directors, and a key securityholder have agreed to 90-day lock-up periods.
TriSalus Life Sciences, Inc. is offering shares of its common stock pursuant to a preliminary prospectus supplement dated February 19, 2026. The prospectus supplement supplements a shelf registration and describes the terms and mechanics of a primary offering of Common Stock listed on Nasdaq as "TLSI."
The filing discloses preliminary unaudited financial context: estimated Q4 2025 revenue of $13.2 million, full-year 2025 revenue of $45.2 million, and approximately $20.4 million of cash and cash equivalents as of December 31, 2025. The company states net proceeds will be used for general corporate purposes and that underwriting details, offering price and number of shares are set forth in the prospectus supplement (subject to completion).
TriSalus Life Sciences, Inc. director Michael P. Stansky reported receiving a grant of stock options to buy 92,537 shares of common stock at an exercise price of $4.91 per share. The options vest in three equal annual installments starting on February 4, 2027, contingent on his continued service with the company.
TriSalus Life Sciences director Michael P. Stansky reported his existing ownership in a new Form 3 filing. He beneficially owns 543,232 shares of TriSalus common stock and a warrant exercisable for 827,500 shares of common stock at an exercise price of $11.50 per share, expiring on August 10, 2028.
The filing also reports 82,500 shares of common stock owned by Skyview Investments LLC, where Stansky is the managing member and exercises voting and dispositive power. All of these securities were acquired before he became a director, effective February 4, 2026.
TriSalus Life Sciences, Inc. announced a board change, with Dr. Arjun “JJ” Desai resigning as a director effective February 3, 2026. His resignation is stated to be unrelated to any disagreement over the company’s operations, policies, or practices.
The company appointed veteran healthcare investor Michael P. Stansky to its Board of Directors effective February 4, 2026. He will serve on the Audit Committee, Compensation Committee, and Science and Technology Committee. TriSalus highlighted his 40 years of investment management and healthcare experience, including senior roles at Tudor Investment Corporation and Wellington Management.
TriSalus Life Sciences, Inc. filed a current report to note that it issued a press release with preliminary, unaudited financial results for the fourth quarter and full year ended December 31, 2025, along with 2026 revenue guidance. The company attached this press release as Exhibit 99.1 and incorporated it by reference for informational purposes. The report also clarifies that the press release and related information are being furnished rather than filed, which limits their exposure to certain securities law liabilities.